GenSpera’s Injectable Prodrug Formulations Enters National Phase with Patent Application


GenSpera, Inc. (OTCQB: GNSZ) recently announced that the patent application “Injectable Cancer Compositions” has entered the national phase application process in 17 countries and regions across Europe, Asia, as well as Brazil and the United States. The purpose of the patent, when awarded, is to extend the exclusivity period for GenSpera’s core intellectual property around its entire platform technology until 2033. This will also include lead drug candidate, mipsagargin.

The patent applications claims composition-of-matter for an injectable form of thapsigargin-containing prodrugs which has demonstrated both physical and chemical stability under appropriate storage conditions. These claims include a lyophilized emulsion form of the drugs. The injectable form of the drugs is not only easier to administer to patients compared to the standard infusion, but also is more easily stored and transported to a patient site.

“These types of patents are extremely important in building true intrinsic value in GenSpera’s core assets,” said Craig A. Dionne, Ph.D., GenSpera’s chief executive officer. “Not only do they extend patent life in all major markets, they also expand opportunities for use by non-oncologists, such as urologists and other primary caregivers, who may not have easy access to infusion bays to deliver drugs. This aspect of drug life-cycle management has been particularly appreciated during our discussions with potential licensing partners.”

About GenSpera

GenSpera, Inc. is a San Antonio-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for targeted release of drug candidates within tumors. GenSpera’s lead drug candidate, mipsagargin, was granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).

For additional information on GenSpera, visit and connect on Twitter, LinkedIn,Facebook, YouTube and Google+.

Cautionary Statement Regarding Forward Looking Information

This communication may contain forward-looking statements. Investors are cautioned that statements in this document regarding potential applications of GenSpera’s technologies or the future prospects of the company constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights and the acceptance of GenSpera’s proposed therapies by the health community. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera’s periodic reports filed with the Securities and Exchange Commission.



About Author

Leave A Reply